Quince Therapeutics
QNCX
44 hedge funds and large institutions have $7.71M invested in Quince Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 42 → 44 (+2)
0% less ownership
Funds ownership: 0.09% → 0.08% (-0%)
2% less capital invested
Capital invested by funds: $7.83M → $7.71M (-$119K)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$199K |
| 2 |
Renaissance Technologies
New York
|
+$76.5K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$33.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$32.8K |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$338K |
| 2 |
Jane Street
New York
|
-$126K |
| 3 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$30.3K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.5K |
| 5 |
Two Sigma Advisers
New York
|
-$15.9K |
QNCX Hedge Fund Activity: Q1 2024 in Review
44 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2024, worth a combined $7.71M — down 1.5% from $7.83M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new QNCX positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $199K. The largest seller was Tang Capital Management, cutting an estimated $338K.
- 44 institutional investors held Quince Therapeutics (QNCX) as of Q1 2024, up from 42 in Q4 2023.
- Funds reported $7.71M of Quince Therapeutics stock for Q1 2024, down 1.5% quarter-over-quarter.
- 7 funds opened new Quince Therapeutics positions in Q1 2024 and 5 closed out, a net change of +2 holders.
- The largest Quince Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $199K added.
- The largest Quince Therapeutics seller in Q1 2024 was Tang Capital Management, an estimated $338K sold.
Based on aggregated 13F filings for Q1 2024.